Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Femicept is a combined oral contraceptive tablet containing two active ingredients: levonorgestrel (150 micrograms) and ethinylestradiol (30 micrograms)[2][8]. It belongs to the class of estrogen-progestogen combination contraceptives, commonly referred to as "the Pill." The primary mechanism of action is inhibition of ovulation via suppression of the hypothalamo-pituitary–ovarian axis, specifically preventing the mid-cycle surge in luteinising hormone. Additional contraceptive effects include thickening cervical mucus to impede sperm penetration and altering the endometrium to reduce receptivity for implantation[2]. Femicept is indicated for pregnancy prevention. Its efficacy and safety are supported by bioequivalence studies comparing it with established reference products such as Microgynon 30[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on femicept.